TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2018

Conditions
Dengue
Interventions
BIOLOGICAL

TDENV-PIV

Single-dose vial with pre-filled syringe, subcutaneous injection

BIOLOGICAL

TDENV-F17

Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly

OTHER

Placebo

0.5 mL vial

Trial Locations (1)

13210

Upstate Medical University, SUNY, Syracuse

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

GlaxoSmithKline

INDUSTRY

lead

U.S. Army Medical Research and Development Command

FED